Download free PDF

Inhaled Nitric Oxide Delivery System Market Size & Share 2026-2035

Report ID: GMI13452
   |
Published Date: November 2026
 | 
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:

Inhaled Nitric Oxide Delivery System Market Size

The inhaled nitric oxide delivery system market was valued at USD 375 million in 2025, is projected to advance to USD 415 million in 2026, and is expected to grow at a CAGR of 7.0% from 2026 to 2035, reaching USD 765 million by the end of the forecast period.

Inhaled Nitric Oxide Delivery System Market Key Takeaways

2025 Market Size
$ 375 Million
2026 Market Size
$ 415 Million
2035 Forecast Market Size
$ 765 Million
CAGR (2026–2035)
7%
Regional Dominance
Largest Market
North America
Fastest Growing Region
Asia Pacific
Key Players
  • Market Leader: Mallinckrodt Pharmaceuticals led with over 26.1% market share in 2025.

  • Leading Players: Top 5 players in this market include Mallinckrodt Pharmaceuticals, Linde (incl. Praxair), Air Liquide Healthcare, Beyond Air, EKU Elektronik, which collectively held a market share of 61.9% in 2025.

The inhaled nitric oxide delivery system market comprises the devices, monitoring hardware, patient interfaces, and consumables used to administer inhaled nitric oxide in clinical care. Demand is evolving beyond legacy cylinder-dependent configurations as hospitals weigh transport readiness, workflow integration, supply reliability, and recurring consumable requirements when renewing critical-care equipment fleets.

GMI Analyst View

Based on our analysis of procurement records, clinical deployment data, and expert consultations with industry participants across care settings, the inhaled nitric oxide delivery system market expanded at a 9.2% CAGR (2022-2025). This momentum reflected post-pandemic NICU capacity restoration, broader adult acute-care utilization, and early deployment of next-generation cylinder-free systems across hospital networks.

Inhaled Nitric Oxide Delivery System Market Trends, Growth Drivers & GMI Forecast Outlook

The market's outlook rests on an established neonatal treatment base and widening demand for flexible, integrated delivery platforms. Procurement is increasingly shaped by whether a system can reduce operational friction while maintaining the monitoring, training, and service capabilities required in high-acuity respiratory care.

Key Drivers

DriverEvidence signalMarket-demand implicationGMI forecast condition
Rising global burden of PPHN and hypoxic respiratory failure in neonatesPPHN affects approximately 1.8 per 1,000 live births globally [2]Sustained institutional demand for certified iNO delivery hardware in NICU settings worldwideNeonatal segment drives baseline procurement stability through 2035, anchoring facility-level device contracts
Expanding NICU admission rates create incremental iNO device utilizationIn the U.S., 9.8% of all births required NICU admission in 2023 [1]Higher device deployment density per NICU; increased disposable throughput per care episodeNorth American procurement rates remain elevated, supporting the region's dominant revenue position through the forecast period
Cylinder-free and portable iNO delivery platforms lower operational barriers to site adoptionMultiple regulatory submissions for next-generation generation-based iNO delivery systems filed across major jurisdictions in 2024-2025, targeting in-hospital transport and ambulatory capabilityExpands addressable device base beyond traditional NICU-anchored cylinder systems; reduces logistical barriers for converting facilitiesAccelerates replacement cycle and broadens site penetration, supporting above-baseline demand through 2030

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Neonatal respiratory failure creates a durable clinical basis for inhaled nitric oxide system placement because care providers require dependable delivery, monitoring, and clinical-support infrastructure at the point of therapy. This supports recurring procurement not only for installed systems, but also for the interfaces, sensors, and breathing-circuit components associated with each treatment episode.

Higher-acuity neonatal admissions also influence fleet density inside hospitals. As NICUs expand their capacity and capability, providers need systems that can be deployed across multiple care settings while fitting established respiratory-therapy workflows. The result is a more persistent demand cycle than one-time capital purchasing alone would suggest.

Cylinder-free and portable configurations alter the commercial equation by reducing reliance on gas-cylinder handling and improving the practicality of in-hospital transport. Manufacturers that can pair mobility with dependable monitoring, simple setup, and service support are better positioned to participate in replacement decisions as providers reassess legacy equipment architectures.

Key Restraints

RestraintEvidence signalMarket-demand implicationGMI forecast condition
High hourly therapy cost limits adoption in budget-constrained settingsiNO therapy is estimated at approximately USD 220 per hour in clinical use [3]Procurement concentrated among well-capitalized academic and tertiary hospitals; limited utilization at community and district-level facilitiesCost-driven barriers slow market penetration in MEA and Latin America through 2030; adoption rates remain below clinical opportunity in cost-sensitive regions
Per-patient therapy expenditure burdens NICU budgets and restricts device fleet expansionMedian iNO cost of USD 7,695 per neonate patient documented in a U.S. clinical cohort study [4]Hospitals face budget trade-offs between iNO device fleet capacity and competing critical care investmentsLimits lower-tier hospital device adoption even as clinical demand rises; disposable purchase volumes track below system capacity in cost-sensitive facilities
Mandatory real-time NO2 and methemoglobin monitoring requirements add device complexity and operational costClinical use protocols require continuous NO2 monitoring below 5 ppm and methemoglobin surveillance during all therapy sessions; integrated monitoring hardware is a certified system componentIncreases system acquisition cost and necessitates specialized operator training, narrowing the adopter baseDrives demand toward integrated monitoring-capable systems rather than modular configurations; reinforces purchasing concentration among advanced-generation platforms

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

The economics of therapy can limit utilization even where the clinical need is evident. Hospitals must evaluate recurring treatment costs alongside capital spending, clinical staffing, and alternative critical-care investments, which can delay system upgrades or narrow access to specialist centers with established therapy programs.

Budget pressure has a second-order effect on fleet planning. Providers with constrained reimbursement or centralized procurement processes may retain legacy systems longer, defer additional placements, or limit therapy availability to the most acute cases. This creates a marked difference between clinical opportunity and addressable commercial demand in cost-sensitive settings.

Monitoring obligations further raise the operational threshold for adoption. Integrated systems must support safe administration while fitting the protocols of respiratory therapists, intensivists, and nursing teams. Those requirements favor suppliers able to provide validated hardware, training, maintenance, and responsive technical support rather than a standalone delivery component.

GMI Analyst View

We see the market's growth as a contest between clinical expansion and operational affordability. The most resilient demand will come from providers that treat delivery hardware, monitoring capability, consumable continuity, and staff readiness as one integrated purchasing decision rather than as separate equipment choices.

Inhaled Nitric Oxide Delivery System Market Segment Analysis

By Age Group

The neonatal segment generated USD 206 million in 2025 and is projected to account for 48.1% of global revenue by 2035. The inhaled nitric oxide delivery system market remains anchored in neonatal care because persistent pulmonary hypertension and related respiratory failure demand tightly controlled administration in NICU environments. Established treatment protocols, specialist staffing, and installed critical-care infrastructure make this segment the foundation for recurring system and disposable demand.

Inhaled Nitric Oxide Delivery System Market Size By Age Group 2025 And 2035 Usd Million
Inhaled Nitric Oxide Delivery System Market Size By Age Group 2025 And 2035 Usd Million

The pediatric segment is expected to reach USD 153 million by 2035, after accounting for 20.0% of the market in 2025. Pediatric utilization is supported by critical-care and surgical settings where pulmonary vascular management is clinically relevant, while shared infrastructure across neonatal and pediatric intensive-care units can lower the operational barrier to adopting compatible delivery platforms.

The adult segment accounted for 25.0% of the market in 2025 and is expected to generate USD 244 million by 2035. Adult demand is increasingly connected to acute hypoxemic respiratory failure and complex ICU care, where compatibility with adult ventilator workflows, transport capability, and clinician familiarity with iNO administration influence system-selection decisions.

By Application

The hypoxic respiratory failure segment generated USD 188 million in 2025 and is expected to represent 43.1% of global revenue by 2035. It remains the principal procurement anchor for providers maintaining dedicated neonatal respiratory-care capacity, because the application requires dependable access to validated delivery and monitoring systems throughout the treatment pathway.

Acute hypoxemic respiratory failure is projected to reach USD 306 million by 2035 and is expected to grow at an 8.5% CAGR (2026-2035). Its expansion reflects broader interest in adult critical-care use cases and favors platforms that can integrate with a wider range of ventilator configurations, enabling suppliers to address ICU needs beyond the historical neonatal core.

Other applications accounted for 14.9% of the market in 2025 and are expected to reach USD 129 million by 2035. This category creates an avenue for incremental utilization in cardiac surgery, transplantation, and specialized pulmonary-care settings, although commercial uptake depends on clinical protocols, reimbursement, and provider confidence in managing the therapy outside core neonatal indications.

By Product

The disposables segment generated USD 206 million in 2025 and is projected to account for 59.1% of global revenue by 2035. Recurring demand for breathing circuits, patient interfaces, sensors, connectors, and related components gives the segment a utilization-linked revenue profile that becomes more important as providers adopt newer device configurations with distinct consumable requirements.

Inhaled Nitric Oxide Delivery System Market Share By Product 2025
Inhaled Nitric Oxide Delivery System Market Share By Product 2025

The system segment is expected to reach USD 313 million by 2035 and expand at a 6.0% CAGR (2026-2035). System purchases are shaped by replacement cycles, hospital-standardization decisions, and the shift toward integrated platforms that combine delivery, safety monitoring, workflow support, and greater mobility within acute-care facilities.

By End Use

Hospitals generated USD 319 million in 2025 and are projected to hold 81.0% of global revenue by 2035. Their prominence reflects the concentration of NICUs, ICUs, respiratory-therapy departments, and specialist clinical teams required for iNO use. Hospital purchasing decisions also tend to favor vendors that can provide equipment service, consumable continuity, and clinical implementation support across large care networks.

Ambulatory centers are projected to reach USD 115 million by 2035 and grow at an 11.3% CAGR (2026-2035). Their expansion depends on portable and cylinder-free systems that can make treatment more practical outside traditional inpatient environments, subject to the evolution of reimbursement, care protocols, and appropriate monitoring arrangements.

Clinics accounted for 4.8% of the market in 2025 and are expected to reach USD 30 million by 2035. Adoption in this setting remains selective, concentrated among specialized providers with the staff capability and clinical governance required to manage nitric oxide delivery safely in an outpatient-oriented environment.

GMI Analyst View

We believe segment value is moving toward care pathways that reward flexibility and repeat utilization. Suppliers with credible portable platforms and consumable models can broaden their opportunity, but only when their systems fit the clinical controls and service expectations that continue to define respiratory-care purchasing.

Inhaled Nitric Oxide Delivery System Market Regional Analysis

Inhaled Nitric Oxide Delivery System Market Share By Region 2025 And 2035
Inhaled Nitric Oxide Delivery System Market Share By Region 2025 And 2035

North America Inhaled Nitric Oxide Delivery System Market Analysis

North America generated USD 176 million in 2025 and is expected to expand at a 6.2% CAGR (2026-2035). The inhaled nitric oxide delivery system market in the region benefits from advanced NICU and ICU infrastructure, established respiratory-therapy practices, and a supplier base able to support regulatory compliance, field service, and multiyear hospital contracts.

U.S.

The U.S. accounted for 90.9% of North American revenue in 2025 and is expected to grow at a 6.1% CAGR (2026-2035). Its market is shaped by large hospital systems, dense critical-care capacity, and an active replacement cycle for devices that offer improved workflow integration, transport capability, and monitoring functionality.

Canada

Canada is expected to reach USD 32 million by 2035 and grow at a 7.3% CAGR (2026-2035). Provincial procurement structures can extend evaluation timelines, but they also support durable supplier relationships when systems meet clinical, service, and value requirements for neonatal and transport care.

Europe Inhaled Nitric Oxide Delivery System Market Analysis

Europe accounted for 26.1% of global revenue in 2025 and is projected to reach USD 184 million by 2035. The region's demand is supported by mature hospital infrastructure and established neonatal-care pathways, while market entry and replacement decisions are influenced by regulatory requirements, national procurement systems, and demonstrated clinical-support capability.

Germany

Germany represented 22.5% of European revenue in 2025 and is expected to reach USD 40 million by 2035. University hospitals and specialist pediatric centers provide an important base for equipment renewal, particularly where providers are assessing the operational advantages of integrated next-generation delivery systems.

U.K.

The U.K. is projected to reach USD 33 million by 2035 and grow at a 6.0% CAGR (2026-2035). Demand is supported by structured NHS procurement pathways and specialist neonatal and transport settings where portability and compatibility with existing respiratory-care workflows can shape supplier selection.

France

France generated USD 15 million in 2025 and is expected to account for 14.7% of European revenue by 2035. Its opportunity is tied to established neonatal-care procurement patterns, with device replacement and service reliability remaining more consequential than broad new-site adoption.

Asia Pacific Inhaled Nitric Oxide Delivery System Market Analysis

Asia Pacific is expected to reach USD 206 million by 2035 and grow at a 10.0% CAGR (2026-2035). The region combines expanding neonatal critical-care capacity with increasingly sophisticated hospital procurement, creating an opportunity for suppliers that can balance clinical performance, service coverage, and affordability across heterogeneous healthcare systems.

China

China generated USD 22 million in 2025 and is projected to account for 33.0% of Asia Pacific revenue by 2035. Continued investment in maternal and child health infrastructure and the expansion of provincially distributed advanced-care services support demand, while registration and local commercial execution remain central to market access.

India

India is expected to reach USD 42 million by 2035 and expand at a 12.8% CAGR (2026-2035). The market's potential is underpinned by a large neonatal care need and an expanding hospital base, although cost sensitivity and uneven access to advanced critical-care infrastructure will keep adoption concentrated in higher-capability facilities.

Japan

Japan accounted for 26.7% of Asia Pacific revenue in 2025 and is expected to reach USD 40 million by 2035. Demand is principally linked to equipment renewal in a mature critical-care environment, with suppliers competing on dependable support, established clinical familiarity, and compatibility with existing care workflows.

South Korea

South Korea is projected to reach USD 20 million by 2035 and grow at a 9.1% CAGR (2026-2035). Its advanced hospital infrastructure and integrated-care environment support adoption of systems that can work effectively alongside domestic ventilator platforms and locally supported clinical-service networks.

Latin America Inhaled Nitric Oxide Delivery System Market Analysis

Latin America is expected to reach USD 31 million by 2035 and grow at a 6.9% CAGR (2026-2035). Demand remains concentrated in leading private and tertiary-care facilities, while public-sector budget constraints, reimbursement limitations, and import-related costs continue to restrict wider diffusion of high-cost specialty respiratory systems.

Brazil

Brazil generated USD 7 million in 2025 and is projected to account for 48.4% of Latin American revenue by 2035. Private hospital networks and urban tertiary centers are likely to remain the principal purchasers of advanced delivery platforms, supported by demand for specialized neonatal and critical-care services.

Mexico

Mexico is expected to reach USD 8 million by 2035 and grow at a 6.6% CAGR (2026-2035). The opportunity is strongest in private hospital groups with advanced NICU capability, while public procurement cycles and formulary limits remain meaningful constraints on system placement.

MEA Inhaled Nitric Oxide Delivery System Market Analysis

MEA generated USD 11 million in 2025 and is expected to reach USD 15 million by 2035. The market is limited by uneven NICU infrastructure, import costs, and healthcare-financing constraints, although selected Gulf markets continue to support demand through hospital-capacity investment and specialist care expansion.

Saudi Arabia

Saudi Arabia accounted for 36.4% of MEA revenue in 2025 and is expected to reach USD 6 million by 2035. Government-led hospital investment and the expansion of pediatric and neonatal critical-care capacity create the region's strongest conditions for commercial deployment of advanced iNO delivery platforms.

UAE

The UAE generated USD 3 million in 2025 and is expected to grow at a 2.2% CAGR (2026-2035). Demand is concentrated in high-capability hospital networks, where procurement is more likely to reflect device renewal and service expectations than broad-based expansion into new care settings.

GMI Analyst View

We expect regional competition to hinge on the ability to translate product differentiation into workable local deployment models. Faster-growing markets offer meaningful demand potential, but suppliers will need to match clinical education, channel support, pricing discipline, and regulatory execution to the realities of each healthcare system.

Inhaled Nitric Oxide Delivery System Market Share & Competitive Landscape

The inhaled nitric oxide delivery system market share remains concentrated, with the top five companies collectively holding 61.9% of global revenue in 2025. This concentration reflects high regulatory and clinical-validation requirements, the importance of established hospital relationships, and the advantage of companies that can combine delivery hardware, monitoring capability, consumables, and technical support.

Mallinckrodt Pharmaceuticals held a 26.1% market share in 2025. Its competitive position is reinforced by the INOmax franchise and hospital relationships built around established neonatal respiratory-care use. The company's nationwide rollout of the INOmax EVOLVE DS system in U.S. hospitals strengthened its device-refresh strategy by emphasizing integrated operation, portability, and electronic medical-record connectivity [7].

Linde, including Praxair, held a 14.7% market share in 2025. The company benefits from an extensive healthcare-gas and service footprint, which is especially relevant where hospitals prefer a coordinated arrangement for gas supply, delivery equipment, maintenance, and clinical support. Its filing for the NOxBox I Plus system illustrates the importance of maintaining a competitive device roadmap alongside its distribution infrastructure [6].

Air Liquide Healthcare held a 12.8% market share in 2025. Its position reflects an integrated healthcare-gas model and established institutional reach across European, Middle Eastern, and international markets. In procurement environments requiring documented service coverage and technical support, this infrastructure can materially strengthen supplier credibility.

Beyond Air represents a differentiated competitive model centered on cylinder-free nitric oxide generation. Its PMA supplement submission for LungFit PH II highlighted a smaller, lighter, transport-ready platform designed to extend the practical use of its technology across hospital and transport settings [5]. EKU Elektronik competes through specialized nitric oxide delivery and monitoring capabilities, while other participants address adjacent opportunities in neonatal transport, critical-care integration, ambulatory delivery, and respiratory-care equipment support.

Recent Industry Developments

Beyond Air Submits PMA Supplement for LungFit PH II (June 2025). Beyond Air submitted a PMA supplement to the U.S. FDA for LungFit PH II, a next-generation therapeutic nitric oxide generator intended to offer a smaller, lighter, and transport-ready configuration. The submission underscores the strategic value of portability and operational simplification in expanding use beyond conventional fixed-site delivery settings [5].

Linde Submits 510(k) for NOxBox I Plus (February 2025). Linde Gas & Equipment filed a 510(k) premarket notification with the U.S. FDA for NOxBox I Plus, its next-generation nitric oxide delivery and monitoring system. The filing signals continued competitive investment in ventilator compatibility and streamlined device operation [6].

Mallinckrodt Completes Nationwide U.S. Rollout of EVOLVE DS (October 2024). Mallinckrodt announced the expanded U.S. hospital rollout of its INOmax EVOLVE DS delivery system, advancing a platform designed to support automated setup, portable operation, and clinical-data connectivity. The development reinforces the importance of device modernization in defending established hospital accounts [7].

Need a specific section of this report?

Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.


Authors:  Monali Tayade, Sampada Kulkarni

Frequently Asked Questions (FAQs):

The inhaled nitric oxide delivery system market size was estimated at USD 375 million in 2025 and is expected to reach USD 415 million in 2026.
The market is projected to reach USD 765 million by 2035, growing at a CAGR of 7.0% from 2026 to 2035.
North America currently holds the largest share of the inhaled nitric oxide delivery system market in 2025.
Asia Pacific is projected to be the fastest-growing region during the forecast period.
Some of the major players in inhaled nitric oxide delivery system market include Mallinckrodt Pharmaceuticals, Linde (incl. Praxair), Air Liquide Healthcare, Beyond Air, EKU Elektronik.

Research methodology, data sources & validation process

This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.

Our 6-step research process

  1. 1. Research design & analyst oversight

    At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.

    Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.

  2. 2. Primary research

    Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.

  3. 3. Data mining & market analysis

    Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.

  4. 4. Market sizing

    Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.

  5. 5. Forecast model & key assumptions

    Every forecast includes explicit documentation of:

    • ✓ Key growth drivers and their assumed impact

    • ✓ Restraining factors and mitigation scenarios

    • ✓ Regulatory assumptions and policy change risk

    • ✓ Technology adoption curve parameter

    • ✓ Macroeconomic assumptions (GDP growth, inflation, currency)

    • ✓ Competitive dynamics and market entry/exit expectations

  6. 6. Validation & quality assurance

    The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.

    Our triple-layer validation process ensures maximum data reliability:

    • ✓ Statistical Validation

    • ✓ Expert Validation

    • ✓ Market Reality Check

Trust & credibility

10+
Years in Service
Consistent delivery since establishment
A+
BBB Accreditation
Professional standards & satisfaction
ISO
Certified Quality
ISO 9001-2015 Certified Company
150+
Research Analysts
Across 20+ industry verticals
95%
Client Retention
5-year relationship value

Verified data sources

  • Trade publications

    Industry journals, trade publications, and specialized media.

  • Industry databases

    Proprietary and third-party market databases

  • Regulatory filings

    Government procurement records and policy documents

  • Academic research

    University studies and specialist institution reports

  • Company reports

    Annual reports, investor presentations, and filings

  • Expert interviews

    C-suite, procurement leads, and technical specialists

  • GMI archive

    13,000+ published studies across 20+ industry verticals

  • Trade data

    Import/export volumes, HS codes, and customs records

Parameters studied & evaluated

Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →

Authors:  Monali Tayade, Sampada Kulkarni
We use cookies to enhance user experience. (Privacy Policy)